Safety and Effectiveness Study of Insulin Glargine (LANTUS) Initiation and Titration in Patients With Type 2 Diabetes

Inclusion criteria: * Patients with a diagnosis of type 2 diabetes for more than 6 months * Patients treated with Oral AntiDiabetics (OADs monotherapy or combination) with an HbA1c \>7% and \<10% and/or treated with NPH insulin with HbA1c \>7% and \<10% or treated with NPH insulin who have experienced severe and/or nocturnal hypoglycemia in the last 6 months. * Ability to perform SMBS and insulin self-titration under the physicians guidance. * Body Mass Index (BMI) \>21 kg/ m2. * Signature of informed consent. Exclusion criteria: * Hospitalized patients. * Pregnant women or with the intention of becoming pregnant. * Unexplained weight loss of more than 10% in the last 6 months. * Women with child bearing potential not using effective contraceptive methods. * Women in breast feeding period. * Patients on chronic treatment with systemic corticosteroids or protease inhibitors. * History of drug or alcohol abuse. * Diabetic retinopathy with surgical treatment in 3 months previous to study entry or patients that could require surgical treatment in the following 6 months to study entry. * Major systemic disease clinically important that would interfere with implementation or interpretation of the study, at the discretion of the investigator. * Renal failure known as creatinine \> 1.4 mg/dl in women and \> 1.5 mg/dl in men. * Known hypersensitivity to glargine or any of its excipients. * Patients with history of hospitalization due to cardiovascular event, cardiovascular procedure in the past 6 months. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.